Loading...

CPIX CUMBERLAND PHARMACEUTICALS INC Product Launches 8-K Filing

CMBR

CPX

CUMBERLAND PHARMACEUTICALS INC

(CPIX)

2025 8-K

Show Summary

Summary

Financial Statements

Clinical Trial Update

Financial Results

Product Approval

Stock Offering Increase

FDA Designation Granted

Financial Results

Research Publication

Medicare Reimbursement

Financial Results

Financial Results

Annual Meeting of Shareholders

At-the-Market Offering Program

Financial Results

Financial Results Announcement

Clinical Study Results

Financial Results

Interim Analysis Results fo...

FDA Waiver Granted

Appointment of Accountant

Change in Accounting Firm

FDA Approval for Caldolor L...

Earnings Report

Annual Meeting of Shareholders

Medicare Reimbursement

FDA Waiver Refund

Compensatory Arrangements o...

Financial Results

Departure of Directors

External Links:

Cumberland Pharmaceuticals announced positive results from its Phase 2 trial of ifetroban, a new oral therapy for heart disease in Duchenne muscular dystrophy patients, marking a significant breakthrough.

AI Assistant

CUMBERLAND PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.